Min-Young Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Min-Young Lee has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Ho Sang Jung
School of Biomedical Engineering, Korea University, Seoul, Korea
10 shared publications - Sung-Gyu Park
Nano-Bio Convergence Department, Korea Institute of Materials Science (KIMS), Changwon, 51508, Republic of Korea
8 shared publications Ayoung Woo
Medical Device Research Center, Samsung Medical Center, Seoul, 06351, Republic of Korea
5 shared publicationsJi Young Lee
Advanced Bio and Healthcare Materials Research Division, Korea Institute of Materials Science (KIMS); 797, Changwon-daero, Seongsan-gu, Changwon-si, Gyeongsangnam-do, Republic of Korea
5 shared publicationsChaeWon Mun
Advanced Bio and Healthcare Materials Research Division, Korea Institute of Materials Science (KIMS), Changwon, Gyeongnam, 51508, Republic of Korea
4 shared publicationsHyun-Ju Park
Department of Medical Device Management and Research, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, 06351, Korea
4 shared publications
Latest Publications
- Open Access
- 2 May 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
Translational feasibility of a plasmonic microarray–based liquid biopsy for KRAS codon mutation detection across tissue, plasma, and urine in early colorectal cancer
Accurate detection of KRAS codon mutations is essential for precision oncology in colorectal cancer (CRC), yet conventional liquid biopsy methods often lack sufficient sensitivity for rare ctDNA variants, particularly in early diseases. We developed a three-dimensional (3D) plasmonic KRAS microarray integrating blocked recombinase polymerase amplification with plasmon-enhanced fluorescence. Quencher-modified blocking probes suppress wild-type DNA while selectively enabling mutant signal amplification. A single primer–probe set per codon allows comprehensive detection of all substitutions within KRAS codons 12/13, 61, and 146. The platform achieved detection down to 1 fM by direct hybridization and 100 zM after blocked amplification, exceeding conventional PCR and next-generation sequencing sensitivity. Codon-level specificity was validated in CRC cell lines, with distinct signals for each mutation. Clinical analysis of 58 patients showed 100% concordance between tissue, plasma, and urine in mutation-positive malignant cases when sufficient input was available, indicating accurate reflection of tumor profiles. In benign tumors, detection was rare despite tissue mutations, likely due to limited ctDNA release.This plasmonic microarray enables ultra-sensitive, specific, and non-invasive detection, supporting early diagnosis, minimal residual disease monitoring, and longitudinal CRC management.
- 2 May 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
Open AccessTranslational feasibility of a plasmonic microarray–based liquid biopsy for KRAS codon mutation detection across tissue, plasma, and urine in early colorectal cancer
Accurate detection of KRAS codon mutations is essential for precision oncology in colorectal cancer (CRC), yet conventional liquid biopsy methods often lack sufficient sensitivity for rare ctDNA variants, particularly in early diseases. We developed a three-dimensional (3D) plasmonic KRAS microarray integrating blocked recombinase polymerase amplification with plasmon-enhanced fluorescence. Quencher-modified blocking probes suppress wild-type DNA while selectively enabling mutant signal amplification. A single primer–probe set per codon allows comprehensive detection of all substitutions within KRAS codons 12/13, 61, and 146. The platform achieved detection down to 1 fM by direct hybridization and 100 zM after blocked amplification, exceeding conventional PCR and next-generation sequencing sensitivity. Codon-level specificity was validated in CRC cell lines, with distinct signals for each mutation. Clinical analysis of 58 patients showed 100% concordance between tissue, plasma, and urine in mutation-positive malignant cases when sufficient input was available, indicating accurate reflection of tumor profiles. In benign tumors, detection was rare despite tissue mutations, likely due to limited ctDNA release.This plasmonic microarray enables ultra-sensitive, specific, and non-invasive detection, supporting early diagnosis, minimal residual disease monitoring, and longitudinal CRC management.
- Open Access
- 5 July 2025
- Published by Elsevier in International Journal of Electrochemical Science
- Vol. 20 (10)
Development of electrochemical sensors based on plasma-treated polymeric nanostructures for sensitive and reproducible detection of bisphenol A
- 5 July 2025
- Published by Elsevier in International Journal of Electrochemical Science
- Vol. 20 (10)
Open AccessDevelopment of electrochemical sensors based on plasma-treated polymeric nanostructures for sensitive and reproducible detection of bisphenol A
- Open Access
- 8 May 2025
- Published by Wiley in Advanced Science
- Vol. 12 (29) , e2503257
Plasmonic Molecular Entrapment for Label‐Free Methylated DNA Detection and Machine‐Learning Assisted Quantification
Epigenetic DNA methylations are linked to the activation of oncogenes and inactivation of tumor suppressor genes. A reliable and label‐free method to quantitatively measure DNA methylation levels is essential for diagnosing and monitoring methylation‐related diseases. Herein, plasmonic molecular entrapment (PME) method assisted SERS as facile strategy for trapping and label‐free sensing of DNA methylation, utilizing in situ surface growth of plasmonic particle in the presence of target analytes, are developed. This highly sensitive and adaptable technique forms hotspot sites around target analytes, overcoming mismatch geometrical properties and producing a strong electromagnetic field that leads to significant SERS signal enhancement. The PME method effectively profiles and quantifies DNA methylation, demonstrating robust capabilities for DNA analysis. A logistic regression (LR)‐based machine learning accurately quantifies and classifies methylation levels in clinical serum samples of colorectal cancer and normal patients with high sensitivity, specificity, and accuracy, highlighting the feasibility of this technique. The developed PME method combined with machine learning offers promising sensing techniques for disease screening and diagnosis, marking a significant advancement in disease detection and patient care.
- 8 May 2025
- Published by Wiley in Advanced Science
- Vol. 12 (29) , e2503257
Open AccessPlasmonic Molecular Entrapment for Label‐Free Methylated DNA Detection and Machine‐Learning Assisted Quantification
Epigenetic DNA methylations are linked to the activation of oncogenes and inactivation of tumor suppressor genes. A reliable and label‐free method to quantitatively measure DNA methylation levels is essential for diagnosing and monitoring methylation‐related diseases. Herein, plasmonic molecular entrapment (PME) method assisted SERS as facile strategy for trapping and label‐free sensing of DNA methylation, utilizing in situ surface growth of plasmonic particle in the presence of target analytes, are developed. This highly sensitive and adaptable technique forms hotspot sites around target analytes, overcoming mismatch geometrical properties and producing a strong electromagnetic field that leads to significant SERS signal enhancement. The PME method effectively profiles and quantifies DNA methylation, demonstrating robust capabilities for DNA analysis. A logistic regression (LR)‐based machine learning accurately quantifies and classifies methylation levels in clinical serum samples of colorectal cancer and normal patients with high sensitivity, specificity, and accuracy, highlighting the feasibility of this technique. The developed PME method combined with machine learning offers promising sensing techniques for disease screening and diagnosis, marking a significant advancement in disease detection and patient care.
- Open Access
AI‐Assisted Plasmonic Diagnostics Platform for Osteoarthritis and Rheumatoid Arthritis With Biomarker Quantification Using Mathematical Models
Osteoarthritis (OA) and rheumatoid arthritis (RA) are major causes of functional impairment, disability, and chronic pain, leading to a substantial rise in healthcare costs. Despite differences in pathophysiology, these diseases share overlapping features that complicate diagnosis, necessitating early, more accurate, and cost‐effective diagnostic tools. This study introduces an innovative plasmonic diagnostics platform for rapid and accurate label‐free diagnosis of OA and RA. The sensing platform utilizes a highly dense urchin‐like gold nanoarchitecture (UGN), which enhances the surface plasmonic area to significantly amplify the Raman signal. The feasibility of the developed platform for arthritis diagnosis is demonstrated by analyzing the synovial fluid (SVF) of patients. Assisted by a machine learning model, Raman signals of OA and RA groups are successfully classified with high clinical sensitivity and specificity. Metabolic biomarkers are further investigated using mathematical models of combined Pearson correlation coefficient (PCC) and non‐negative matrix factorization (NMF), suggesting valuable insights for arthritis biomarker quantification. In addition, RA severity is studied using the sensing platform by classifying results from the hematology test, achieving successful stage discrimination. This platform offers a versatile, affordable, and scalable in‐clinic arthritis diagnostic solution with potential applications in diagnosing and monitoring other diseases through biofluid analysis.
Open AccessAI‐Assisted Plasmonic Diagnostics Platform for Osteoarthritis and Rheumatoid Arthritis With Biomarker Quantification Using Mathematical Models
Osteoarthritis (OA) and rheumatoid arthritis (RA) are major causes of functional impairment, disability, and chronic pain, leading to a substantial rise in healthcare costs. Despite differences in pathophysiology, these diseases share overlapping features that complicate diagnosis, necessitating early, more accurate, and cost‐effective diagnostic tools. This study introduces an innovative plasmonic diagnostics platform for rapid and accurate label‐free diagnosis of OA and RA. The sensing platform utilizes a highly dense urchin‐like gold nanoarchitecture (UGN), which enhances the surface plasmonic area to significantly amplify the Raman signal. The feasibility of the developed platform for arthritis diagnosis is demonstrated by analyzing the synovial fluid (SVF) of patients. Assisted by a machine learning model, Raman signals of OA and RA groups are successfully classified with high clinical sensitivity and specificity. Metabolic biomarkers are further investigated using mathematical models of combined Pearson correlation coefficient (PCC) and non‐negative matrix factorization (NMF), suggesting valuable insights for arthritis biomarker quantification. In addition, RA severity is studied using the sensing platform by classifying results from the hematology test, achieving successful stage discrimination. This platform offers a versatile, affordable, and scalable in‐clinic arthritis diagnostic solution with potential applications in diagnosing and monitoring other diseases through biofluid analysis.
- Open Access
- 29 October 2024
- Published by Springer Nature in Microchimica Acta
- Vol. 191 (11) , 1-12
Nanoplasmonic microarray–based solid-phase amplification for highly sensitive and multiplexed molecular diagnostics: application for detecting SARS-CoV-2
A novel approach is introduced using nanoplasmonic microarray–based solid-phase recombinase polymerase amplification (RPA) that offers high sensitivity and multiplexing capabilities for gene detection. Nanoplasmonic microarrays were developed through one-step immobilization of streptavidin/biotin primers and fine-tuning the amplicon size to achieve high plasmon-enhanced fluorescence (PEF) on the nanoplasmonic substrate, thereby improving sensitivity. The specificity and sensitivity of solid-phase RPA on nanoplasmonic microarrays was evaluated in detecting E, N, and RdRP genes of SARS-CoV-2. High specificity was achieved by minimizing primer-dimer formation and employing a stringent washing process and high sensitivity obtained with a limit of detection of four copies per reaction within 30 min. In clinical testing with nasopharyngeal swab samples (n = 30), the nanoplasmonic microarrays demonstrated a 100% consistency with the PCR results for detecting SARS-CoV-2, including differentiation of Omicron mutations BA.1 and BA.2. This approach overcomes the sensitivity issue of solid-phase amplification, as well as offers rapidity, high multiplexing capabilities, and simplified equipment by using isothermal reaction, making it a valuable tool for on-site molecular diagnostics. Graphical abstract
- 29 October 2024
- Published by Springer Nature in Microchimica Acta
- Vol. 191 (11) , 1-12
Open AccessNanoplasmonic microarray–based solid-phase amplification for highly sensitive and multiplexed molecular diagnostics: application for detecting SARS-CoV-2
A novel approach is introduced using nanoplasmonic microarray–based solid-phase recombinase polymerase amplification (RPA) that offers high sensitivity and multiplexing capabilities for gene detection. Nanoplasmonic microarrays were developed through one-step immobilization of streptavidin/biotin primers and fine-tuning the amplicon size to achieve high plasmon-enhanced fluorescence (PEF) on the nanoplasmonic substrate, thereby improving sensitivity. The specificity and sensitivity of solid-phase RPA on nanoplasmonic microarrays was evaluated in detecting E, N, and RdRP genes of SARS-CoV-2. High specificity was achieved by minimizing primer-dimer formation and employing a stringent washing process and high sensitivity obtained with a limit of detection of four copies per reaction within 30 min. In clinical testing with nasopharyngeal swab samples (n = 30), the nanoplasmonic microarrays demonstrated a 100% consistency with the PCR results for detecting SARS-CoV-2, including differentiation of Omicron mutations BA.1 and BA.2. This approach overcomes the sensitivity issue of solid-phase amplification, as well as offers rapidity, high multiplexing capabilities, and simplified equipment by using isothermal reaction, making it a valuable tool for on-site molecular diagnostics. Graphical abstract
- Open Access
- 8 August 2024
- Published by Wiley in Small Science
- Vol. 4 (8)
Highly Sensitive 3D‐Nanoplasmonic‐Based Epidermal Growth Factor Receptor Mutation Multiplex Assay Chip for Liquid Biopsy
- 8 August 2024
- Published by Wiley in Small Science
- Vol. 4 (8)
Open AccessHighly Sensitive 3D‐Nanoplasmonic‐Based Epidermal Growth Factor Receptor Mutation Multiplex Assay Chip for Liquid Biopsy
- Open Access
- 3 August 2024
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 264, 116633
Machine learning-assisted label-free colorectal cancer diagnosis using plasmonic needle-endoscopy system
- 3 August 2024
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 264, 116633
Open AccessMachine learning-assisted label-free colorectal cancer diagnosis using plasmonic needle-endoscopy system
- Open Access
- 26 June 2024
- Published by Wiley in Small Science
- Vol. 4 (8) , 2400101
Highly Sensitive 3D‐Nanoplasmonic‐Based Epidermal Growth Factor Receptor Mutation Multiplex Assay Chip for Liquid Biopsy
Economical mutation detection method with high analytical and clinical sensitivity is necessary for early cancer diagnosis and screening. In this study, a novel 3D‐nanoplasmonic‐based multiplex mutation assay chip is developed to detect epidermal growth factor receptor (EGFR) mutations. This assay kit comprises a 3D‐nanoplasmonic substrate immobilized with capture probes and primer–probe sets for recombinase polymerase amplification, wild‐type inhibition, and fluorescence detection, enabling multiplex detection of EGFR exon 19 deletions, exon 20 insertions, and exon 21 L858R point mutations. The strategy facilitates the detection of all deletions and insertions within the target region with extremely high analytical sensitivity, detecting as low as 1 × 10−9% mutation frequency, implying three copies/reactions and 100 zM. The synergistic effects of plasmon‐enhanced fluorescence from the 3D‐nanoplasmonic substrate and wild‐type inhibitor contribute to this high analytical sensitivity. Moreover, the developed chip exhibits 100% accuracy in the clinical testing of plasma samples from normal individuals and patients with benign lung tumor and malignant lung tumor. With high sensitivity and multiplexing capabilities, this assay operates at a low reaction temperature (around 37 °C) and requires a short processing time, ≈70 min post‐cell‐free DNA extraction. These features make the chip a valuable tool for easy and widespread cancer screening.
- 26 June 2024
- Published by Wiley in Small Science
- Vol. 4 (8) , 2400101
Open AccessHighly Sensitive 3D‐Nanoplasmonic‐Based Epidermal Growth Factor Receptor Mutation Multiplex Assay Chip for Liquid Biopsy
Economical mutation detection method with high analytical and clinical sensitivity is necessary for early cancer diagnosis and screening. In this study, a novel 3D‐nanoplasmonic‐based multiplex mutation assay chip is developed to detect epidermal growth factor receptor (EGFR) mutations. This assay kit comprises a 3D‐nanoplasmonic substrate immobilized with capture probes and primer–probe sets for recombinase polymerase amplification, wild‐type inhibition, and fluorescence detection, enabling multiplex detection of EGFR exon 19 deletions, exon 20 insertions, and exon 21 L858R point mutations. The strategy facilitates the detection of all deletions and insertions within the target region with extremely high analytical sensitivity, detecting as low as 1 × 10−9% mutation frequency, implying three copies/reactions and 100 zM. The synergistic effects of plasmon‐enhanced fluorescence from the 3D‐nanoplasmonic substrate and wild‐type inhibitor contribute to this high analytical sensitivity. Moreover, the developed chip exhibits 100% accuracy in the clinical testing of plasma samples from normal individuals and patients with benign lung tumor and malignant lung tumor. With high sensitivity and multiplexing capabilities, this assay operates at a low reaction temperature (around 37 °C) and requires a short processing time, ≈70 min post‐cell‐free DNA extraction. These features make the chip a valuable tool for easy and widespread cancer screening.
- Top Cited Papers
- 12 February 2024
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 251, 116128
Surface-functionalized SERS platform for deep learning-assisted diagnosis of Alzheimer's disease
- 12 February 2024
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 251, 116128
Top Cited PapersSurface-functionalized SERS platform for deep learning-assisted diagnosis of Alzheimer's disease